{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:23:07Z","timestamp":1759335787718,"version":"3.40.5"},"reference-count":28,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Objective: To determine the role of the IL8 rs4073 polymorphism in predicting the risk of central nervous system (CNS) toxicity in patients receiving standard pharmacological treatment for multidrug-resistant tuberculosis (MDR-TB). Methods: A cohort of 85 consenting MDR-TB patients receiving treatment with second-line antituberculosis drugs had their blood samples amplified for the IL8 (rs4073) gene and genotyped. All patients were clinically screened for evidence of treatment toxicity and categorized accordingly. Crude and adjusted associations were assessed. Results: The chief complaints fell into the following categories: CNS toxicity; gastrointestinal toxicity; skin toxicity; and eye and ear toxicities. Symptoms of gastrointestinal toxicity were reported by 59% of the patients, and symptoms of CNS toxicity were reported by 42.7%. With regard to the genotypes of IL8 (rs4073), the following were identified: AA, in 64 of the study participants; AT, in 7; and TT, in 11. A significant association was found between the dominant model of inheritance and CNS toxicity for the crude model (p = 0.024; OR = 3.57; 95% CI, 1.18-10.76) and the adjusted model (p = 0.031; OR = 3.92; 95% CI, 1.13-13.58). The AT+TT genotype of IL8 (rs4073) showed a 3.92 times increased risk of CNS toxicity when compared with the AA genotype. Conclusions: The AT+TT genotype has a tendency to be associated with an increased risk of adverse clinical features during MDR-TB treatment.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20230338","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T15:28:10Z","timestamp":1705418890000},"page":"e20230338","source":"Crossref","is-referenced-by-count":3,"title":["Role of the IL8 rs4073 polymorphism in central nervous system toxicity in patients receiving multidrug-resistant tuberculosis treatment"],"prefix":"10.36416","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-4468","authenticated-orcid":false,"given":"Ibrahim","family":"Mohammed Badamasi1","sequence":"first","affiliation":[{"name":"1. Pharmacogenomic Unit, Department of Human Anatomy, Faculty of Basic Medical Sciences \u2013 FBMS \u2013 College of Medicine, Bayero University, Kano, Kano, Nigeria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8632-7762","authenticated-orcid":false,"given":"Muktar","family":"Muhammad1","sequence":"additional","affiliation":[{"name":"1. Pharmacogenomic Unit, Department of Human Anatomy, Faculty of Basic Medical Sciences \u2013 FBMS \u2013 College of Medicine, Bayero University, Kano, Kano, Nigeria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6736-1267","authenticated-orcid":false,"given":"Aishat","family":"Ahmad Umar1","sequence":"additional","affiliation":[{"name":"1. Pharmacogenomic Unit, Department of Human Anatomy, Faculty of Basic Medical Sciences \u2013 FBMS \u2013 College of Medicine, Bayero University, Kano, Kano, Nigeria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6450-3241","authenticated-orcid":false,"given":"Umm-ayman","family":"Misbahu Madugu1","sequence":"additional","affiliation":[{"name":"1. Pharmacogenomic Unit, Department of Human Anatomy, Faculty of Basic Medical Sciences \u2013 FBMS \u2013 College of Medicine, Bayero University, Kano, Kano, Nigeria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0061-5219","authenticated-orcid":false,"given":"Muktar","family":"Ahmed Gadanya2","sequence":"additional","affiliation":[{"name":"2. Department of Community Medicine, Faculty of Clinical Sciences, Bayero University, Kano, Kano, Nigeria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1484-2837","authenticated-orcid":false,"given":"Isa","family":"Abubakar Aliyu3","sequence":"additional","affiliation":[{"name":"3. Department of Medical Laboratory Science, Faculty of Allied Health Sciences \u2013 FAHS \u2013 Bayero University, Kano, Kano, Nigeria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2645-7282","authenticated-orcid":false,"given":"Imam","family":"Malik Kabir3","sequence":"additional","affiliation":[{"name":"3. Department of Medical Laboratory Science, Faculty of Allied Health Sciences \u2013 FAHS \u2013 Bayero University, Kano, Kano, Nigeria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8128-3422","authenticated-orcid":false,"given":"Ibrahim","family":"Aliyu Umar4","sequence":"additional","affiliation":[{"name":"4. Kano State TB and Leprosy Control Program, Kano State Ministry of Health, Kano, Nigeria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6842-4616","authenticated-orcid":false,"given":"Ochigbo","family":"Johnson5","sequence":"additional","affiliation":[{"name":"5. Kano State Infectious Disease Hospital, Kano State Ministry of Health, Kano, Nigeria."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6938-954X","authenticated-orcid":false,"given":"Johnson","family":"Stanslas6","sequence":"additional","affiliation":[{"name":"6. Pharmacotherapeutics Lab, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22288","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.Harshavardhan S, Vijayakumar KK, Sounderrajan V, Ramasamy P, Rajadas SE. Basics of tuberculosis disease and principles of treatment and their effects. In: Rajan M, editor. A Mechanistic Approach to Medicines for Tuberculosis Nanotherapy. London: Academic Press; 2021. p. 1-29. https:\/\/doi.org\/10.1016\/B978-0-12-819985-5.00011-5","DOI":"10.1016\/b978-0-12-819985-5.00011-5"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.Dinic L, Akande P, Idigbe EO, Ani A, Onwujekwe D, Agbaji O, et al. Genetic determinants of drug-resistant tuberculosis among HIV-infected patients in Nigeria. J Clin Microbiol. 2012;50(9):2905-2909. https:\/\/doi.org\/10.1128\/JCM.00982-12","DOI":"10.1128\/jcm.00982-12"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.Gonzalez Y, Guzm\u00e1n-Beltr\u00e1n S, Carreto-Binaghi LE, & Ju\u00e1rez E. Translational research for therapy against tuberculosis. In: Kesharwani P, editor. Nanotechnology Based Approaches for Tuberculosis Treatment. London: Academic Press; 2020. p. 53-73.doi:10.1016\/b978-0-12-819811-7.00004-7 https:\/\/doi.org\/10.1016\/B978-0-12-819811-7.00004-7","DOI":"10.1016\/b978-0-12-819811-7.00004-7"},{"key":"ref3","unstructured":"4.World Health Organization. Global Health TB Report. Geneva: World Health Organization; 2018. ISBN 978-92-4-156564-6"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.Kaona FA, Tuba M, Siziya S, Sikaona L. An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health. 2004;4:68. https:\/\/doi.org\/10.1186\/1471-2458-4-68","DOI":"10.1186\/1471-2458-4-68"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.Girling DJ. Adverse effects of antituberculosis drugs. Drugs. 1982;23(1-2):56-74. https:\/\/doi.org\/10.2165\/00003495-198223010-00003","DOI":"10.2165\/00003495-198223010-00003"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41 Suppl 2:S144-S157. https:\/\/doi.org\/10.1086\/428055","DOI":"10.1086\/428055"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.Schwartz MT, Calvert JF. Potential neurologic toxicity related to ciprofloxacin. DICP. 1990;24(2):138-140. https:\/\/doi.org\/10.1177\/106002809002400204","DOI":"10.1177\/106002809002400204"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. 2007;27(8):1189-1197. https:\/\/doi.org\/10.1592\/phco.27.8.1189","DOI":"10.1592\/phco.27.8.1189"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS Drugs. 2010;24(8):655-667. https:\/\/doi.org\/10.2165\/11534340-000000000-00000","DOI":"10.2165\/11534340-000000000-00000"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603-662. https:\/\/doi.org\/10.1164\/rccm.167.4.603","DOI":"10.1164\/rccm.167.4.603"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.Menon V, Jain D, Saxena R, Sood R. Prospective evaluation of visual function for early detection of ethambutol toxicity. Br J Ophthalmol. 2009;93(9):1251-1254. https:\/\/doi.org\/10.1136\/bjo.2008.148502","DOI":"10.1136\/bjo.2008.148502"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.Costa GN, Magno LA, Santana CV, Konstantinovas C, Saito ST, Machado M, et al. Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs. Mol Diagn Ther. 2012;16(4):241-250. https:\/\/doi.org\/10.1007\/BF03262213","DOI":"10.1007\/bf03262213"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.Mattingly CJ, Rosenstein MC, Davis AP, Colby GT, Forrest JN Jr, Boyer JL. The comparative toxicogenomics database: a cross-species resource for building chemical-gene interaction networks. Toxicol Sci. 2006;92(2):587-595. https:\/\/doi.org\/10.1093\/toxsci\/kfl008","DOI":"10.1093\/toxsci\/kfl008"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.Garc\u00eda-Elorriaga G, Carrillo-Montes G, Mendoza-Aguilar M, Gonz\u00e1lez-Bonilla C. Polymorphisms in tumor necrosis factor and lymphotoxin A in tuberculosis without and with response to treatment. Inflammation. 2010;33(4):267-275. https:\/\/doi.org\/10.1007\/s10753-010-9181-8","DOI":"10.1007\/s10753-010-9181-8"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.Peresi E, Oliveira LR, da Silva WL, da Costa EA, Araujo JP Jr, Ayres JA, et al. Cytokine Polymorphisms, Their Influence and Levels in Brazilian Patients with Pulmonary Tuberculosis during Antituberculosis Treatment. Tuberc Res Treat. 2013;2013:285094. https:\/\/doi.org\/10.1155\/2013\/285094","DOI":"10.1155\/2013\/285094"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.Motsinger AA, Ritchie MD. Multifactor dimensionality reduction: an analysis strategy for modelling and detecting gene-gene interactions in human genetics and pharmacogenomics studies. Hum Genomics. 2006 Mar;2(5):318-28. https:\/\/doi.org\/10.1186\/1479-7364-2-5-318","DOI":"10.1186\/1479-7364-2-5-318"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.Piras D, Zoledziewska M, Cucca F, Pani A. Genome-Wide Analysis Studies and Chronic Kidney Disease. Kidney Dis (Basel). 2017;3(3):106-110. https:\/\/doi.org\/10.1159\/000481886","DOI":"10.1159\/000481886"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.Deguchi T. Physiology and molecular biology of arylamine N-acetyl transferases. Biomed Res. 1992;13:231-242. https:\/\/doi.org\/10.2220\/biomedres.13.231","DOI":"10.2220\/biomedres.13.231"},{"key":"ref19","unstructured":"20.World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug- Resistant Tuberculosis. Geneva: World Health Organization; 2014. Available from: https:\/\/ncbi.nlm.nih.gov\/books\/NBK247420\/?term=Companion%20Handbook%20to%20the%20WHO%20Guidelines%20for%20the%20Programmatic%20Management%20of%20Drug-%20Resistant%20Tuberculosis"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.Wu CC, Huang YK, Huang CY, Shiue HS, Pu YS, Su CT, et al. Polymorphisms of TNF-a -308 G\/A and IL-8 -251 T\/A Genes Associated with Urothelial Carcinoma: A Case-Control Study. Biomed Res Int. 2018;2018:3148137. https:\/\/doi.org\/10.1155\/2018\/3148137","DOI":"10.1155\/2018\/3148137"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.Onyedum CC, Alobu I, Ukwaja KN. Prevalence of drug-resistant tuberculosis in Nigeria: A systematic review and meta-analysis. PLoS One. 2017;12(7):e0180996. https:\/\/doi.org\/10.1371\/journal.pone.0180996","DOI":"10.1371\/journal.pone.0180996"},{"key":"ref22","unstructured":"23.Zhang J, Han X, Sun S. IL-8 -251A\/T and +781C\/T polymorphisms were associated with risk of breast cancer in a Chinese population. Int J Clin Exp Pathol. 2017;10(7):7443-7450."},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.Akahane M, Watanabe M, Inoue N, Miyahara Y, Arakawa Y, Inoue Y, et al. Association of the polymorphisms of chemokine genes (IL8, RANTES, MIG, IP10, MCP1 and IL16) with the pathogenesis of autoimmune thyroid diseases. Autoimmunity. 2016;49(5):312-319. https:\/\/doi.org\/10.3109\/08916934.2015.1134507","DOI":"10.3109\/08916934.2015.1134507"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J. 2006;8(1):E48-E54. https:\/\/doi.org\/10.1208\/aapsj080106","DOI":"10.1208\/aapsj080106"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.Bourdi M, Masubuchi Y, Reilly TP, Amouzadeh HR, Martin JL, George JW, et al. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology. 2002;35(2):289-298. https:\/\/doi.org\/10.1053\/jhep.2002.30956","DOI":"10.1053\/jhep.2002.30956"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.Chen J, Ma A. Associations of polymorphisms in interleukins with tuberculosis: Evidence from a meta-analysis. Immunol Lett. 2020;217:1-6. https:\/\/doi.org\/10.1016\/j.imlet.2019.10.012","DOI":"10.1016\/j.imlet.2019.10.012"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.Hacking D, Knight JC, Rockett K, Brown H, Frampton J, Kwiatkowski DP, et al. In-creased in vivo transcription of an IL-8 haplotype associated with respiratory syncytial virus disease-susceptibility. Genes Immun. 2004;5(4):274-282. https:\/\/doi.org\/10.1038\/sj.gene.6364067","DOI":"10.1038\/sj.gene.6364067"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T15:28:20Z","timestamp":1705418900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jornaldepneumologia.com.br\/details\/3912\/en-US\/role-of-the-il8-rs4073-polymorphism-in-central-nervous-system-toxicity-in-patients-receiving-multidrug-resistant-tuberculosis-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":28,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20230338","relation":{},"ISSN":["1806-3756"],"issn-type":[{"type":"electronic","value":"1806-3756"}],"subject":[],"published":{"date-parts":[[2024,1,16]]}}}